Potential prognostic value of HER2/CEP17 FISH ratio in HER2-positive non-metastatic breast cancer: a real-world study
Abstract Background HER2-positive breast cancer (BC) requires anti-HER2 therapy. We aimed to determine whether the expression of the HER2/centromeric probe for chromosome 17 (CEP17) ratio was associated with prognosis in patients with HER2-positive non-metastatic BC. Methods 267 HER2-positive BC wer...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-05-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-02495-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract Background HER2-positive breast cancer (BC) requires anti-HER2 therapy. We aimed to determine whether the expression of the HER2/centromeric probe for chromosome 17 (CEP17) ratio was associated with prognosis in patients with HER2-positive non-metastatic BC. Methods 267 HER2-positive BC were enrolled between January 2010 and December 2011. Stabilized inverse probability treatment weighting (sIPTW) was used to balance baseline characteristics. Real-world disease-free survival (DFS) and overall survival (OS) was analyzed. Results The median follow-up time was 10.3 years (interquartile range: 9.4–10.8 years). HER2/CEP17 ratio of > 7.0 was defined as the HER2 ultra-positive group; a HER2/CEP17 ratio of ≤ 7.0 was defined as the HER2 normal-positive group. After sIPTW adjustment, no differences were observed in DFS and OS when anti-HER2 therapy was unknown, and similarly in the patients who were recorded as not receive trastuzumab (all p > 0.05). Interestingly, HER2 ultra-positive group had a worse DFS than the normal-positive group (hazard ratio [HR] = 2.72, p = 0.02), but there was no difference in OS (p = 0.30) in patients did receive trastuzumab. The multivariate Cox models also showed that the HER2 ultra-positive had worse DFS than HER2 normal-positive patients (HR = 3.71; p < 0.01). Conclusion For non-metastatic HER2-positive BC with or without trastuzumab treatment, the HER2/CEP17 ratio did not predict DFS and OS. However, our study supported that HER2 ultra-positive group had a worse DFS than the normal-positive group among non-metastatic HER2-positive BC patients receiving trastuzumab; therefore, this could be a potential predictor of DFS in these patients. |
|---|---|
| ISSN: | 2730-6011 |